Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT

Bone Marrow Transplantation

Volumn 48, Issue 1, 2013, Pages 146-147

  Armand, P ^a   Sainvil, M M ^a   Kim, H T ^a   Rhodes, J ^b   Cutler, C ^a   Ho, V T ^a   Koreth, J ^a   Alyea, E P ^a   Neufeld, E J ^c   Kwong, R Y ^d   Soiffer, R J ^a   Antin, J H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; FERRITIN;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FERRITIN BLOOD LEVEL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HYPOTENSION; IRON CHELATION; IRON OVERLOAD; LETTER; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; CHELATION THERAPY; DEFEROXAMINE; DRUG MONITORING; EARLY TERMINATION OF CLINICAL TRIALS; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; IRON CHELATING AGENTS; IRON OVERLOAD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84872165422     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.94     Document Type: Letter

References (10)

1. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588. (Pubitemid 46743431)
2. Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versushost disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146: 310-316.
3. Platzbecker U, Bornhauser M, Germing U, Stumpf J, Scott BL, Kroger N et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008; 14: 1217-1225.
4. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799-805.
5. Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110: 1303-1306. (Pubitemid 47435602)
6. Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T. Non-transferrinbound iron during allogeneic stem cell transplantation. Br J Haematol 2001; 113: 836-838. (Pubitemid 32524411)
7. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403-409. (Pubitemid 20000236)
8. Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 852-860.
9. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009; 114: 3064-3073.
10. Fukushima T, Kawabata H, Nakamura T, Iwao H, Nakajima A, Miki M et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 2011; 31: 1741-1744.